Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
株式のランク #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
株価
$0.01292666
最終同期: 2025-04-08
時価総額
$157.54K
変化(1日)
6.84%
変化(1年)
0.00%
GB
取引 Synairgen plc (SNG)

カテゴリー

Synairgen plc(SNG)のEPS
June 2024 時点のEPS TTM: $-0.04
Synairgen plcの最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-0.04です。2022年末には、EPSは$-0.11で、2021年のEPS$-0.32と減少でした。
Synairgen plcのEPS履歴(2004から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-0.04 -13.00%
2023 $-0.05 -49.81%
2022 $-0.11 -67.33%
2021 $-0.32 150.97%
2020 $-0.13 176.28%
2019 $-0.05 5.88%
2018 $-0.04 -274.70%
2017 $0.03 -166.75%
2016 $-0.04 4.12%
2015 $-0.04 -273.33%
2014 $0.02 -146.98%
2013 $-0.04 -11.13%
2012 $-0.05 -41.31%
2011 $-0.09 34.96%
2010 $-0.06 -65.03%
2009 $-0.18 -7.49%
2008 $-0.20 44.55%
2007 $-0.14 67.04%
2006 $-0.08 39.93%
2005 $-0.06 112.04%
2004 $-0.03 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -39,916.09%
US
$27.74 -63,870.11%
NL
- -
CH
- -
KR
$13.70 -31,594.48%
BE